|
|
 |
|
Viewing report
|
|
|
|
Nanotechnology for Drug Discovery and Drug Design
Decision Resources, Inc., Aug 2005, Pages: 16
Nanotechnology, a field of science and technology that aims to control matter at the atomic, molecular, and macromolecular level, potentially has far-reaching and paradigm-shifting implications for biology, drug discovery, and medical technologies. The discipline has already yielded discoveries that have been used for drug delivery and diagnostic purposes, and nanotech applications coming to market will include more of the same, in addition to uses in preclinical assays and other assay technologies. Nanotechnology, however, has uses in many fields besides biomedical science. Governments have recognized the broad reach of nanotechnology, and they have poured large sums of money into nanotech R&D to ensure their future competitiveness. This investment has already yielded many discoveries in the field, and it is broadening opportunities for nanotechnology in drug discovery and research.
In this report, we describe various nanotechnologies under development for biological and medical purposes and assess their potential. We also highlight the activities of companies applying nanotechnology to the biological and medical sciences.
Business Implications
- Nanotechnology is an emerging science that could have far-reaching and paradigm-shifting implications for biology, drug discovery, and medical technologies. Nanotechnologies for biological applications already in use include liposomal drug-delivery agents, transfection agents, and magnetic resonance imaging contrast agents. An important advantage of nanotechnology will be its ability to enable and improve upon other technologies, including RNA interference, gene delivery, and proteomics.
- Multifunctional nanoparticles that combine targeting, delivery, and imaging components will have important clinical potential but a complex regulatory path. We anticipate that the first and most extensive use of multifunctional nanoparticles will be applications in the area of drug target and lead validation studies. These multifunctional particles and complex combination technologies will carry very complex intellectual property issues that will likely lead to the need for multiparty licensing.
- Many governments have recognized the importance of harnessing nanotechnology to achieve industrial competitiveness and have invested heavily in funding nanotechnology research and innovation. In the absence of private and venture investment, various government initiatives have fostered the growth of numerous nanotechnology companies. These companies have a variety of business models, and many are focused on research tool development, in vivo imaging, and drug delivery.
- Nanotechnology drug-delivery companies seeking to partner with pharmaceutical companies face competition from a plethora of available drug-delivery systems. Nevertheless, pharmaceutical companies may choose to develop their own systems using skills gleaned from corporate partnerships; this approach may be an advantage to nanotechnology companies. We anticipate that pharmaceutical companies will continue to partner with a variety of nanotechnology companies to find the best technologies for drug-delivery and discovery needs.
Customers who bought this item also bought
The Role of Nanotechnology in European Drug Discovery
Nanotechnology: Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics
Biomedical Applications of Nanotechnology
Bio Nanotechnology
Global Market and Applications for Nanotechnology in the Life Sciences and Healthcare Industries
The Nanotechnology Opportunity Report (NOR) 2008, 3rd Edition
Nanotechnology - Global Outlook
Drug Delivery in Cancer - Technologies, Markets and Companies
Nanotechnology Market Opportunities, Strategies, and Forecasts, 2004 to 2009
Innovation in Drug Delivery: The Future of Nanotechnology and Non-invasive Protein Delivery
Nanotechnology in Europe 2009
The Impact of Nanotechnology in Drug Discovery: Global Developments, Market Analysis and Future Prospects
|
|
|
|
